Biodistribution of a Monoclonal Antibody in Small-Cell Lung Cancer
Author Information
Author(s): D Ornadel, JA Ledermann, K Eagle, RB Pedley, G Boxer, SE Ward, Y Olabiran, J Bomanji
Primary Institution: UCL Medical School; Royal Free Hospital School of Medicine
Hypothesis
Can the monoclonal antibody NY3D11 be used for targeted therapy in small-cell lung cancer (SCLC)?
Conclusion
The study found that the antibody NY3D11 did not localize to tumors in patients with SCLC, instead accumulating in the liver and bone marrow.
Supporting Evidence
- NY3D11 localized well to SCLC xenografts in mice.
- Maximum tumor localization occurred at 48 hours after injection.
- Antibody accumulation was observed in the liver and bone marrow in patients.
Takeaway
Researchers tested a special antibody to see if it could find and help treat lung cancer, but it didn't work as expected in patients.
Methodology
The study involved biodistribution studies in nude mice and gamma-camera imaging in patients with SCLC.
Limitations
The antibody did not localize to primary tumors or metastases in patients, which limits its therapeutic potential.
Participant Demographics
Patients aged 16-80 years with small-cell lung cancer, both newly diagnosed and undergoing treatment.
Want to read the original?
Access the complete publication on the publisher's website